Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients

Inclusion Criteria: * Subjects with Type 1 diabetes mellitus included in the phase II therapeutic trial with a humanized non-mitogenic CD3 monoclonal antibody (ChAgly CD3) at time of clinical diagnosis and who agree and are likely to comply with the investigator's instructions Exclusion Criteria: * Any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the patient * Use of illicit drugs or over consumption of alcohol (\> 3 beers/day) * Being legally incapacitated, having significant emotional problems at the time of the study